Evaluation of Clomipramine Against Amyotrophic Lateral Sclerosis in an hSOD1-G93A Mouse Study

By exploiting network medicine and drug repurposing strategies, we previously identified and prioritized clomipramine as one among a subset of suitable non-customary compounds to be tested against amyotrophic lateral sclerosis (ALS). We then investigated the chronic administration of clomipramine in vivo, in the hSOD1-A4V and hSOD1-G85R Drosophila melanogaster ALS models, demonstrating significant efficacy in ameliorating lifespan, improving motor abilities, and mitigating genomic instability and inflammation. The aim of the present work is now to test clomipramine against ALS in the hSOD1-G93A mouse, which remains today among the premier and most exploited and validated preclinical models for studying the disease. Our work demonstrates that the effects of clomipramine are not consistently reproduced across different preclinical models of ALS. In particular, clomipramine emerges as a context-dependent drug in ALS mice. Intraperitoneal administration of clomipramine does not improve overall survival at 10 mg/Kg, but it significantly worsens body weight, motor performance and neuroscore predominantly in male mice. At 20 mg/Kg, clomipramine elicits a clinically meaningful increase in survival time only in the male subgroup, despite a statistically non-significant p-value. Our study reveals the complex profile of clomipramine’s effects, rather than a clear therapeutic action. We trust that further insights and fine tuning through cross-model validation and context-dependent modulation by clomipramine might reveal a novel route for better understanding ALS and exploring clinical outcomes.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-17
DOI
https://doi.org/10.3390/ijms272210296
Primary Topic
Amyotrophic Lateral Sclerosis Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Evaluation of Clomipramine Against Amyotrophic Lateral Sclerosis in an hSOD1-G93A Mouse Study

Monica Armida, Cinzia Volonté, Silvia Bullitta, Rosa Luisa Potenza et al.
1 links
International Journal of Molecular Sciences
Amyotrophic Lateral Sclerosis Research
article

Evaluation of Clomipramine Against Amyotrophic Lateral Sclerosis in an hSOD1-G93A Mouse Study

Monica Armida, Cinzia Volonté, Silvia Bullitta, Rosa Luisa Potenza, Francesco Liguori, Susanna Amadio, Alessio Lauricella, Luca Zanfini
article en

Abstract

By exploiting network medicine and drug repurposing strategies, we previously identified and prioritized clomipramine as one among a subset of suitable non-customary compounds to be tested against amyotrophic lateral sclerosis (ALS). We then investigated the chronic administration of clomipramine in vivo, in the hSOD1-A4V and hSOD1-G85R Drosophila melanogaster ALS models, demonstrating significant efficacy in ameliorating lifespan, improving motor abilities, and mitigating genomic instability and inflammation. The aim of the present work is now to test clomipramine against ALS in the hSOD1-G93A mouse, which remains today among the premier and most exploited and validated preclinical models for studying the disease. Our work demonstrates that the effects of clomipramine are not consistently reproduced across different preclinical models of ALS. In particular, clomipramine emerges as a context-dependent drug in ALS mice. Intraperitoneal administration of clomipramine does not improve overall survival at 10 mg/Kg, but it significantly worsens body weight, motor performance and neuroscore predominantly in male mice. At 20 mg/Kg, clomipramine elicits a clinically meaningful increase in survival time only in the male subgroup, despite a statistically non-significant p-value. Our study reveals the complex profile of clomipramine’s effects, rather than a clear therapeutic action. We trust that further insights and fine tuning through cross-model validation and context-dependent modulation by clomipramine might reveal a novel route for better understanding ALS and exploring clinical outcomes.

International Journal of Molecular SciencesVol. 27(22)
Istituto Superiore di Sanità (IT), Institute for Systems Analysis (RU), Fondazione Santa Lucia (IT), National Research Council (IT), Istituto di Analisi dei Sistemi ed Informatica Antonio Ruberti (IT)
Consiglio Nazionale delle Ricerche
Good health and well-being
Amyotrophic Lateral Sclerosis Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon